Zelluna Immunotherapy has announced an investment from Takeda Ventures, the strategic investing arm of Takeda.
TVI investment joins Zelluna’s latest financing round, the company states.
“We are delighted to have TVI as a strategic investor in Zelluna. The company has developed very well from its inception and made significant progress with our TCR-NK technology. This investment from TVI opens further opportunities to fully exploit the potential of our TCR-NK products,” says Hans Ivar Robinson, Chairman of the Board of Directors at Zelluna.
The funds will enable the advancement of a lead TCR-NK product through manufacturing to Clinical Trial Application (CTA) / Investigational New Drug Application (IND) readiness and, continue the advancement of Zelluna’s platform with additional programs reaching the preclinical stage, it states.
“The investment by TVI supports our efforts to develop a novel and proprietary TCR-NK technology platform.”
“This announcement signifies a pivotal moment in Zelluna’s evolution. The investment by TVI supports our efforts to develop a novel and proprietary TCR-NK technology platform, and reinforces the strength of our science, IP portfolio, and the expertise of the people across the company. We believe TVI makes for a highly fitting investment partner given Takeda’s immuno-oncology research focus and ongoing efforts to develop allogenic cell therapies. We are excited that TVI shares our view of the potential of the TCR-NK platform technology and look forward to working together on our pioneering journey, ” says Namir Hassan, CEO, Zelluna.
Photo of Namir Hassan: Zelluna